Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (currently amended): A method for identifying a compound [[for]] that modulates XPB or XPD helicase-dependent p53-mediated apoptosis comprising:

(a) providing a biologically active p53 polypeptide, and a XPB or XPD helicase polypeptide, ~~wherein the helicase is selected from the group consisting of XPB and XPD,~~

(b) contacting a compound suspected of inducing XPB or XPD helicase-dependent p53-mediated apoptosis with the polypeptides of step (a)

(c) detecting whether or not the compound is capable of specifically inhibiting binding of the p53 polypeptide to the XPB or XPD helicase, wherein a compound that specifically inhibits the binding of the p53 polypeptide to the XPB or XPD helicase is a compound that modulates helicase-dependent p53-mediated apoptosis.

2-15 (canceled)

16 (previously presented): The method of claim 1, further comprising contacting the polypeptides with a compound that inhibits binding of p53 to XPB or XPD.

17 (previously presented): The method of claim 16, wherein the compound that inhibits binding of p53 to XPB or XPD is HBX.

18 (previously presented): The method of claim 1, further comprising

(d) determining whether the compound suspected of inducing helicase-dependent p53-mediated apoptosis can inhibit helicase activity, wherein a compound that inhibits XPB or XPD helicase activity is a compound that modulates helicase- dependent p53-mediated apoptosis.

19 (previously presented): The method of claim 18, wherein the helicase polypeptide is present as part of a TFIIH transcription complex.

20 (previously presented): The method of claim 1, wherein the p53 polypeptide and the helicase polypeptide are each introduced into a cell.

21 (previously presented): The method of claim 20, wherein at least one of the p53 polypeptide or the helicase polypeptide is a native polypeptide.

22 (previously presented): The method of claim 20, wherein the p53 polypeptide is a wild-type p53 polypeptide.

23 (previously presented): The method of claim 20, wherein the helicase polypeptide is a mutant helicase polypeptide.

24 (previously presented): The method of claim 20, wherein the cell is a member selected from the group consisting of: a fibroblast cell, an epithelial cell, and a hematopoietic cell.